Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695027 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
A Phase 2 study of Primary Open Angle Glaucoma, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT05695027 is a Phase 2 study of Primary Open Angle Glaucoma that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 250 participants, below the 281-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (11% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05695027, a Phase 2 study of Primary Open Angle Glaucoma, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dietary supplements - Nicotinamide and Pyruvate
Study Locations (3)
New York
- ColumbiaDoctors Ophthalmology - 880 Third Avenue - New York
- Columbia University Irving Medical Center - 622 W 168th St - New York
California
- Stanford University Department of Ophthalmology - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05695027
The ClinicalTrials.gov registry entry for NCT05695027 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (11% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05695027 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, California.
Frequently Asked Questions
What is clinical trial NCT05695027 about?
NCT05695027 is a clinical study titled "Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study". The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enroll...
What is the current status of trial NCT05695027?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2023-03-14. Estimated completion is 2028-01.
What conditions does trial NCT05695027 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT05695027?
The interventions under investigation include: Placebo (DRUG), Dietary supplements - Nicotinamide and Pyruvate (DRUG).
Who is sponsoring clinical trial NCT05695027?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05695027 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
RECRUITING · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Ahmed Glaucoma Valve Surgery With Mitomycin-C
COMPLETED · Phase 2
-
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
COMPLETED · Phase 2
-
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.